Bristol myers Squibb Company  (BMY)
Other Ticker:  
Price: $76.9100 $1.11 1.464%
Day's High: $77.245 Week Perf: 0.81 %
Day's Low: $ 76.08 30 Day Perf: -0.77 %
Volume (M): 13,441 52 Wk High: $ 78.17
Volume (M$): $ 1,033,755 52 Wk Avg: $65.65
Open: $76.29 52 Wk Low: $53.22

 Market Capitalization (Millions $) 166,595
 Shares Outstanding (Millions) 2,166
 Employees 30,250
 Revenues (TTM) (Millions $) 46,960
 Net Income (TTM) (Millions $) 6,268
 Cash Flow (TTM) (Millions $) 1,258
 Capital Exp. (TTM) (Millions $) 1,053

Bristol Myers Squibb Company
Bristol-Myers Squibb Company was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. The Company, through its divisions and subsidiaries, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other healthcare related products.

The Company has four reportable segments—Pharmaceuticals, Oncology Therapeutics Network (OTN), Nutritionals and Other Healthcare. The Pharmaceuticals segment is made up of the global pharmaceutical and international (excluding Japan) consumer medicines business. The OTN segment provides oncology products, supportive care products and related supplies to office-based oncologists in the United States. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula business. The Other Healthcare segment consists of ConvaTec, Medical Imaging and Consumer Medicines (North America and Japan) businesses.

In the Company’s Pharmaceuticals segment and in its ConvaTec and Medical Imaging businesses, the Company promotes its products in medical journals and directly to health care providers such as doctors, nurse practitioners, physician assistants, pharmacists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the United States through direct-to-consumer print, radio and television advertising.

The Company’s operations include several pharmaceutical sales organizations. Each sales organization markets a distinct group of products and is typically based on particular therapeutic areas or physician groups. These sales organizations often focus on selling new products when they are introduced, and marketing to physicians is increasingly targeted at specialists and high value primary care physicians.

The Company’s prescription pharmaceutical products are sold principally to wholesalers, but the Company also sells directly to retailers, hospitals, clinics, government agencies and pharmacies. Pharmaceutical wholesalers in the United States are; McKesson Corporation (McKesson), Cardinal and AmerisourceBergen Corporation.


The markets in which Bristol-Myers Squibb competes are generally broad-based and highly competitive. The principal means of competition vary among product categories and business groups.

The Company’s Pharmaceuticals segment competes with other worldwide research-based drug companies, many smaller research companies with more limited therapeutic focus and generic drug manufacturers. Important competitive factors include product efficacy, safety and ease of use, price and demonstrated cost-effectiveness, marketing effectiveness, product labeling, service and research and development of new products and processes. Sales of the Company’s products can be impacted by new studies that indicate a competitor’s product has greater efficacy for treating a disease or particular form of disease than one of the Company’s products.

   Company Address: 430 E. 29th Street, 14FL New York 10016 NY
   Company Phone Number: 546-4200   Stock Exchange / Ticker: NYSE BMY
   BMY is expected to report next financial results on July 27, 2022.

Customers Net Income grew by BMY's Customers Net Profit Margin fell to

2.59 %

4.49 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
LLY        3.51% 
JNJ        0.42% 
MRK        5.34% 
ABT        2.16% 
PFE        4.17% 
ABBV        2.99% 
• View Complete Report

Grupo Financiero Galicia Sa

Profits Surge by Grupo Financiero Galicia Sa in the financial interval ending Dec 31 2021 announcement

In the financial interval ending Dec 31 2021 Grupo Financiero Galicia Sa earnings were up by 20.79 % of $0.55 per share compared to $0.46 a year ago and from $0.00 per share from the previous quarter.

Sinopec Shanghai Petrochemical Company Limited

Profits Soared by 220 % by Sinopec Shanghai Petrochemical Company Limited in the financial time-frame ending Dec 31 2021 announcement

Company displayed pleasant results in the financial time-frame ending Dec 31 2021. Sales were at $13.25 billions higher by 19.53% year on year and by 0 % quarter on quarter, while earnings per share more than doubled by 220 % to $0.03, sequentially by 0 %.

Fanhua Inc

EPS Unchanged by Fanhua Inc in the fourth quarter of 2021 release

Fanhua Inc reported unchanged earnings per share at $0.04 on moderate Sales increase of 2.48% to $513.31 millions in the fourth quarter of 2021 from the same quarter a year ago.

Oneconnect Financial Technology Co Ltd

Break-even, Surge in Sales

Surge in Sales could not lift company's earnings, in the fourth quarter of 2021 reached break-even at $0.00 per share, Sales jumped by 24.76% to $613.66 millions from the same quarter a year ago.

Stealth Biotherapeutics Corp

Stealth Biotherapeutics Corp in the most recent fiscal period

For the most recent fiscal period Stealth Biotherapeutics Corp lost money at $-0.08 per share, compared to results of $-0.10 per share a year ago quarter, In the previous quarter company realized $0.00 per share.


Bristol Myers Squibb's Segments
 Segment    11.45 % of total Revenue
 Segment    10.1 % of total Revenue
 Segment    1.13 % of total Revenue
 Segment    4.1 % of total Revenue
 Segment    8.18 % of total Revenue
 Segment    7.86 % of total Revenue
 Segment    11.89 % of total Revenue
 Segment    45.27 % of total Revenue
Total Pharmaceuticals
 Segment    100 % of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Bristol Myers Squibb does not provide revenue guidance.

Earnings Outlook
Stealth Biotherapeutics Corp does not provide earnings estimates.

Geographic Revenue Dispersion
United States 48.59 %
EMEA 22.62 %
Other 28.79 %


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

OWLT's Profile

Stock Price

OWLT's Financials

Business Description


Charts & Quotes

OWLT's News


OWLT's Competitors

Customers & Markets

Economic Indicators

OWLT's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071